What is Zacks Research's Estimate for TBPH FY2024 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at Zacks Research cut their FY2024 earnings per share (EPS) estimates for Theravance Biopharma in a research report issued to clients and investors on Tuesday, December 3rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($1.06) for the year, down from their previous forecast of ($0.97). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.88 EPS, FY2025 earnings at $0.07 EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at $0.08 EPS and FY2026 earnings at $0.58 EPS.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million for the quarter, compared to analysts' expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the prior year, the business posted ($0.17) earnings per share.

Several other equities analysts have also recently issued reports on TBPH. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. StockNews.com cut shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $13.75.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock traded up $0.04 during trading on Friday, hitting $9.88. 132,468 shares of the company's stock were exchanged, compared to its average volume of 230,087. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71. The stock has a market capitalization of $485.80 million, a price-to-earnings ratio of -9.78 and a beta of 0.23. The business has a 50-day simple moving average of $8.86 and a 200-day simple moving average of $8.72.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 322,743 shares in the company, valued at $2,904,687. This represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently bought and sold shares of TBPH. Squarepoint Ops LLC acquired a new stake in Theravance Biopharma during the 2nd quarter worth $986,000. Bank of Montreal Can boosted its position in Theravance Biopharma by 141.0% during the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock worth $1,414,000 after acquiring an additional 93,702 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company's stock valued at $2,800,000 after acquiring an additional 91,679 shares in the last quarter. Algert Global LLC acquired a new stake in Theravance Biopharma in the 3rd quarter valued at about $851,000. Finally, Marshall Wace LLP lifted its stake in Theravance Biopharma by 83.6% in the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock worth $2,523,000 after purchasing an additional 135,426 shares in the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.